Q-omics provides the consensus-scored DUS4L profile across patient tissues and cancer cell-line models. DUS4L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DUS4L is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, DUS4L RNA expression shows 19,690 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LUAD, and ACC as cancer lineages where DUS4L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUS4L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUS4L survival associations across molecular data types. DUS4L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUS4L RNA expression–survival associations across cancer types. High DUS4L expression shows unfavorable associations in KICH, UVM and LGG, but favorable associations in UCS, SKCM and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for DUS4L RNA expression.
This table summarizes DUS4L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DUS4L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUS4L shows higher tumor expression in LUAD, HNSC, BLCA, COAD, KIRP and LIHC. The LUAD box plot shows higher DUS4L RNA expression in tumor versus normal tissue (log2 FC = +1.255, t-test p < 0.001).
This table shows molecular features associated with DUS4L in patient tissues and cancer cell lines. In patient samples, DUS4L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUS4L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
